Haemonetics Co. (NYSE:HAE) Stake Reduced by AQR Capital Management LLC

AQR Capital Management LLC cut its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 34.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 83,988 shares of the medical instruments supplier's stock after selling 44,787 shares during the quarter. AQR Capital Management LLC owned 0.16% of Haemonetics worth $6,948,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. TFO Wealth Partners LLC raised its position in Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier's stock worth $51,000 after buying an additional 589 shares during the last quarter. Covestor Ltd grew its stake in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 438 shares during the period. Daiwa Securities Group Inc. acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $83,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Haemonetics during the 1st quarter worth approximately $86,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Down 0.2 %

Shares of Haemonetics stock traded down $0.19 on Friday, reaching $77.89. 307,489 shares of the company were exchanged, compared to its average volume of 543,060. The stock's 50 day moving average price is $77.99 and its 200-day moving average price is $84.00. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The company has a market cap of $3.97 billion, a P/E ratio of 34.10, a price-to-earnings-growth ratio of 1.19 and a beta of 0.30. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million for the quarter, compared to analysts' expectations of $335.08 million. During the same quarter last year, the business posted $1.05 earnings per share. The business's revenue was up 8.0% on a year-over-year basis. As a group, equities analysts forecast that Haemonetics Co. will post 4.57 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of a number of analyst reports. BTIG Research initiated coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They set a "buy" rating and a $112.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Needham & Company LLC raised shares of Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 price target on the stock in a research note on Wednesday, June 12th. Citigroup dropped their price target on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, August 22nd. Finally, Bank of America assumed coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and an average target price of $106.14.

Insider Buying and Selling

In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the firm's stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now owns 21,410 shares of the company's stock, valued at approximately $1,926,900. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the firm's stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now owns 21,410 shares of the company's stock, valued at approximately $1,926,900. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the firm's stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company's stock, valued at approximately $1,658,565.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.80% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.